Lyophilized Drugs Market Exhibits a Stunning Growth Potentials | Sanofi S.A., Merck & Co., Inc.& Fresenius Kabi USA
The global lyophilized drugs market was valued at US$ 322.9 billion in 2018, according
to Coherent Market Insights, and is expected to grow at a CAGR of 7.1 percent
over the forecast period (2018–2026). The global lyophilized drugs market
is predicted to rise as regulatory approvals for lyophilized drugs increase. For
example, Novartis Pharmaceuticals Corporation got FDA clearance in September
2018 for its prefilled syringe formulation of Xolair (omalizumab) for the
treatment of moderate to severe persistent allergic asthma and chronic
idiopathic urticarial. The medicine comes in a single-dose vial containing 150
mg of lyophilized, sterile powder for reconstitution.
Furthermore,
in order to strengthen their product portfolio, businesses are pursuing inorganic
growth techniques such as acquisitions and collaborations. For example, in
January 2015, Piramal, an Indian contract manufacturing company, paid US$ 30.65
million for Coldstream Laboratories, a sterile injectable contract development
and manufacturing organization (CDMO) based in the United States.
Active
participation in enhancing vaccine accessibility in low and middle-income
economies by organizations such as GAVI-the Vaccine Alliance, the World Health
Organizations (WHO), and others are projected to boost market expansion. Over 8
million people in Africa will now have access to immunizations thanks to the
increased financing. As a result, such programs are assisting manufacturers
in concentrating their efforts on low and middle-income economies in order to
strengthen their footprint. Furthermore, due to a number of factors, infectious
diseases such as pneumococcal infections, influenza, diphtheria, and others are
particularly common among Africans.
Due to
increased attention of manufacturers on the development of highly advanced
packaging technologies that protect the vial during the lyophilization process
in order to safeguard the drug's purity, the vial segment is predicted to see
substantial growth in the lyophilized medicines market. For example, West
Pharmaceutical Services, Inc. debuted its LyoSeal cap in February 2017.
In the
worldwide lyophilized medicines market, North America is predicted to be the
most appealing region. Factors such as the high presence of key players in the
region and key companies' facility expansion in North America to expand
lyophilized product manufacturing capacity are projected to drive market growth
in this region.
Sanofi S.A.,
Merck & Co., Inc., Fresenius Kabi USA, LLC., Ciron Drugs &
Pharmaceuticals Pvt Ltd., GlaxoSmithKline plc., Mylan NV., Pfizer, Inc., Amneal
Pharmaceuticals LLC, Otsuka Holdings Co., Ltd. (Otsuka Pharmaceutical Co.,
Ltd.), and BTG Plc are among the major companies in the global
Comments
Post a Comment